A combination of flutamide (Eulexin) or nilutamide (Anandron) with a luteinizing hormone-releasing
hormone (LHRH) agonist or orchiectomy is the only therapy demonstrated to prolong
life in prostate cancer. Recently, the low 50-mg daily dose of Casodex, an analogue
of the pure antiandrogen flutamide, was chosen for clinical studies on the basis that
the compound was 5 to 10 times more potent than flutamide, as suggested by data obtained
in the inappropriate intact rat model. The present study was designed to compare the
in vitro antiandrogenic activity of OH-flutamide (OH-FLU), the active metabolite of
flutamide, Casodex, and nilutamide.